Xiaojing Zheng - Publications

Novel small-molecule positive allosteric modulator 1 with blood-brain barrier penetration activity exerts anti-cellular senescence effects via the PAC1-R/YY1/SIRT6 pathway.

Journal: Acta biochimica et biophysica Sinica

Published: March 21, 2026

The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors.

Journal: Journal of ovarian research

Published: November 06, 2024

Risk factors analysis and multidisciplinary team first-aid simulation training for umbilical cord prolapse can improve neonatal outcomes.

Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

Published: May 12, 2024

Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer.

Journal: MedComm

Published: September 05, 2023

The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages.

Journal: Cancer cell international

Published: April 19, 2023

A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: February 02, 2023

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.

Journal: Frontiers in immunology

Published: December 01, 2022

Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner.

Journal: Cancer science

Published: May 31, 2022

Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer.

Journal: BMC cancer

Published: March 10, 2022

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.

Journal: Pathology oncology research : POR

Published: January 01, 2022

Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive Cervical Cancer.

Journal: Pathology oncology research : POR

Published: July 11, 2021